1
|
Horgan D, Pesapane F, Van der Buckle M, de Maria R, Dube F, Singh J, Ługowska I, Bayle A, Hofman P, Malapelle U, Hills T, Capoluongo ED, Subbiah V. From theory to practice: Implementing next-generation sequencing and public health genomics in healthcare systems. Crit Rev Oncol Hematol 2024; 201:104433. [PMID: 38955310 DOI: 10.1016/j.critrevonc.2024.104433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2024] [Revised: 06/24/2024] [Accepted: 06/25/2024] [Indexed: 07/04/2024] Open
Abstract
If Europe's health systems make a conscious decision to increase their utilization of technology and techniques that can enhance prevention and expedite early-stage diagnosis, they can effectively address the growing challenges of disease. By embracing these advancements, these health systems can significantly improve their response to emerging health issues.However, at present the effective integration and exploitation of these opportunities remains hesitant and suboptimal, and health and health services underperform accordingly, with patients suffering from the continuing variations in diagnosis and access to innovation. This paper presents a comprehensive study that examines the current state of various influential disciplines and factors in European countries. It specifically focuses on the adoption of Next Generation Screening technologies and the development stage of Public Health Genomics. The assessment of these areas is presented in the context of a rapidly changing policy environment, which provides an opportunity for a fundamental reconsideration of how and where new tools can be integrated into healthcare systems and routine practices. Top of Form.
Collapse
Affiliation(s)
- Denis Horgan
- European Alliance for Personalised Medicine, Brussels 1040, Belgium; Department of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Faculty of Engineering and Technology, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj 211007, India.
| | - Filippo Pesapane
- Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, Italy
| | | | - Ruggero de Maria
- Institute of General Pathology, Catholic University of the Sacred Heart, Rome 20123, Italy
| | - France Dube
- Astra Zeneca, Concord Pike, Wilmington, DE 19803, USA
| | - Jaya Singh
- European Alliance for Personalised Medicine, Brussels 1040, Belgium
| | - Iwona Ługowska
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, Warsaw 02-781, Poland
| | - Arnaud Bayle
- Drug Development Department (DITEP), Gustave Roussy - Cancer Campus, Université Paris Sacla, Villejuif, France
| | - Paul Hofman
- European Liquid Biopsy Society, Hamburg, Germany
| | - Umberto Malapelle
- Department of Public Health, University Federico II of Naples, Naples 80138, Italy
| | - Tanya Hills
- Boehringer Ingelheim International GmbH, Binger Str. 173, Ingelheim am Rhein 55218, Germany
| | - Ettore D Capoluongo
- Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Naples 80138, Italy; Department of Clinical Pathology, Azienda Ospedaliera San Giovanni Addolorata, Via Amba Aradam 8, Rome 00184, Italy
| | - Vivek Subbiah
- Sarah Cannon Research Institute, Nashville, TN 37203, USA.
| |
Collapse
|
2
|
Aisner DL, Gocke CD, Jones D, Limson M, Morrissette J, Segal JP. The Genomics Organization for Academic Laboratories (GOAL): A vision for a genomics future for academic pathology. Acad Pathol 2023; 10:100090. [PMID: 37583476 PMCID: PMC10424130 DOI: 10.1016/j.acpath.2023.100090] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 05/26/2023] [Accepted: 06/18/2023] [Indexed: 08/17/2023] Open
Abstract
Innovative and self-sustaining clinical genomics laboratories specializing in cutting-edge oncology testing are critical to the success of academic pathology departments and resident and fellow education in molecular pathology. However, the pressures and challenges facing these laboratories are numerous, including the complexities of validating comprehensive cancer next-generation sequencing (NGS) panels, competition from commercial laboratories, and the reimbursement and regulatory hurdles inherent in high-complexity testing. Cross-institutional collaborations, including shared assay content and interpretative frameworks, are a valuable element to academic laboratory success. To address these and other needs, the Genomics Organization for Academic Laboratories (GOAL) was conceived in 2018, incorporated in 2020 and has grown to include 29 participating institutions in 2022. Here, we describe the mission of GOAL, its structure, and the outcomes and projects undertaken in its first years.
Collapse
Affiliation(s)
- Dara L. Aisner
- Department of Pathology, University of Colorado, Denver, CO, USA
| | | | - Daniel Jones
- Department of Pathology, The Ohio State University, Columbus, OH, USA
| | - Melvin Limson
- Genomics Organization for Academic Laboratories and the Association of Pathology Chairs, Wilmington, DE, USA
| | - Jennifer Morrissette
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Jeremy P. Segal
- Department of Pathology, University of Chicago, Chicago, IL, USA
| |
Collapse
|
3
|
Villalona-Calero MA, Malhotra J, Chung V, Xing Y, Gray SW, Hampel H, Gruber S, McDonnell K. Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience. J Clin Med 2023; 12:4061. [PMID: 37373756 DOI: 10.3390/jcm12124061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2023] [Revised: 05/29/2023] [Accepted: 06/12/2023] [Indexed: 06/29/2023] Open
Abstract
Recent data suggest that patients with advanced cancer who participate in biomarker/genomically informed early-stage clinical trials experience clinical benefit. While most early-stage clinical trials are conducted in major academic centers, the majority of cancer patients in the United States are treated in community practices. Here, we describe ongoing efforts at the City of Hope Cancer Center to integrate our network community oncology clinical practices into our academic, centralized biomarker/genomic-driven, early-stage clinical trial program to build an understanding of the approaches that provide the benefits of early-stage clinical trial participation to community patients. Our efforts include three key initiatives: the development of a virtual "Refractory Disease" phase 1 trial matching televideo clinic, the construction of infrastructure to support the expansion of phase 1 clinical trials to a distant regional clinical satellite hub, and the implementation of an enterprise-wide precision medicine, germline, and somatic testing program. Our work at City of Hope may serve as an example to facilitate similar efforts at other institutions.
Collapse
Affiliation(s)
| | - Jyoti Malhotra
- City of Hope National Medical Center, Department of Medical Oncology, Duarte, CA 91010, USA
| | - Vincent Chung
- City of Hope National Medical Center, Department of Medical Oncology, Duarte, CA 91010, USA
| | - Yan Xing
- City of Hope National Medical Center, Department of Medical Oncology, Duarte, CA 91010, USA
| | - Stacy W Gray
- City of Hope National Medical Center, Department of Medical Oncology, Duarte, CA 91010, USA
| | - Heather Hampel
- City of Hope National Medical Center, Department of Medical Oncology, Duarte, CA 91010, USA
| | - Stephen Gruber
- City of Hope National Medical Center, Department of Medical Oncology, Duarte, CA 91010, USA
| | - Kevin McDonnell
- City of Hope National Medical Center, Department of Medical Oncology, Duarte, CA 91010, USA
| |
Collapse
|
4
|
A Genomic Information Management System for Maintaining Healthy Genomic States and Application of Genomic Big Data in Clinical Research. Int J Mol Sci 2022; 23:ijms23115963. [PMID: 35682641 PMCID: PMC9180925 DOI: 10.3390/ijms23115963] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Revised: 05/22/2022] [Accepted: 05/25/2022] [Indexed: 01/19/2023] Open
Abstract
Improvements in next-generation sequencing (NGS) technology and computer systems have enabled personalized therapies based on genomic information. Recently, health management strategies using genomics and big data have been developed for application in medicine and public health science. In this review, I first discuss the development of a genomic information management system (GIMS) to maintain a highly detailed health record and detect diseases by collecting the genomic information of one individual over time. Maintaining a health record and detecting abnormal genomic states are important; thus, the development of a GIMS is necessary. Based on the current research status, open public data, and databases, I discuss the possibility of a GIMS for clinical use. I also discuss how the analysis of genomic information as big data can be applied for clinical and research purposes. Tremendous volumes of genomic information are being generated, and the development of methods for the collection, cleansing, storing, indexing, and serving must progress under legal regulation. Genetic information is a type of personal information and is covered under privacy protection; here, I examine the regulations on the use of genetic information in different countries. This review provides useful insights for scientists and clinicians who wish to use genomic information for healthy aging and personalized medicine.
Collapse
|